A Bacopa monnieri extract marketed by ingredient supplier Samriddh as B-Lit Bacopa was associated with significant improvements to cognitive performance, memory, and emotional wellness in a randomized, double-blind, placebo-controlled trial involving 80 healthy adults. The study was published in the Journal of Psychiatry and Cognitive Behavior.
 
In the study, participants were randomly assigned to either take 300 mg of the supplement or a placebo each morning after breakfast for 12 weeks, with periodic assessments for memory and cognitive function using a series of battery tests. Anxiety and sleep were also assessed throughout the study period, using the Beck Anxiety Inventory and the Pittsburgh Sleep Quality Index.
 
The key findings in the study showed significant improvements in short-term memory, spatial short-term memory, visuo-spatial memory, working memory, and episodic memory compared to placebo. Significant improvements were also found in the cognitive domains of focus and concentration, alertness, reasoning, and mental flexibility.
 
Significant differences were achieved for cognitive benefits in 14 days, while memory improvements reached clinical significance by day 28, the authors noted. An acute effect on concentration was observed within the first three hours of a single dose of B-Lit Bacopa. Additionally, serum cortisol levels were significantly reduced versus baseline, and there was an increase in brain-derived neurotrophic factor (BDNF) by day 84.
 
“This is the most comprehensive single study done on Bacopa and the result of our study demonstrates the potential of Bacopa extract as a safe and effective ingredient to support memory, cognition, stress, and sleep quality in healthy adults,” said Aditya Jain, founder and CEO of Samriddh. “These findings alongside our technology for enhanced bioavailability and absorption signify a step forward in innovation and research for cognitive health and overall well-being.”